Gene Therapy by Taylor, Milton W.
Gene	Therapy:		 I	have	always	been	fascinated	by	gene	therapy,	the	idea	that	one	can	place	a	healthy	gene	(DNA	sequence)	 into	a	vector,	be	 it	virus	or	plasmid	(a	circular	piece	of	DNA,	 like	a	mini-chromosome	found	in	bacteria)	then	into	a	cell,	or	directly	into	a	human	to	repair	or	replace	a	mutant	gene.	The	ultimate	aim	is	to	“cure”	specific	genetic	diseases	by	replacing	the	defective	gene	with	a	normal	one.		In	practice	two	different	approaches	have	been	tried,	in	the	first	usually	lymphocytes	(a	type	of	white	blood	cell)	were	harvested	from	a	patient	with	a	genetic	defect,	grown	in	culture,	a	normal	gene	added	in	the	form	of	DNA	to	the	cells	to	repair	the	affected	function	(this	is	known	as	transformation	or	transfection)	and	after	a	few	rounds	of	cell	replication,	the	transformed	cells	were	transplanted	into	the	individual	from	which	 they	were	originally	harvested.	 	This	 is	known	as	 in	vitro	gene	 therapy.	This	technique	 has	 been	 performed	 successfully	 in	 the	 case	 of	 children	 with	 adenosine	deaminase	(ADA-SCID)	deficiency,	a	severe	condition	of	the	immune	system.	Until	recently	this	 experimental	 approach	was	 not	 approved	 by	 the	US	 FDA,	 but	 performed	 in	 Europe.		The	results	have	been	mixed,	with	a	high	 incidence	of	 leukemia	occurring	 in	many	of	 the	patients.	In	 the	 early	 1990’s	 a	 second	 approach,	 known	 as	 in	 vivo	 gene	 therapy	 was	developed.	 A	 specific	 gene	 is	 inserted	 by	 recombination	 and	 integration	 into	 a	 virus,	 for	example	the	normal	gene	defective	in	cystic	fibrosis	patients,	and	this	recombinant	virus	is	injected	directly	into	patients	with	the	disease.	Adenovirus	-5	used	in	these	experiments,	is	an	 innocuous	 virus,	 occasionally	 associated	 with	 symptoms	 of	 the	 common	 cold.	 This	approach	has	been	only	partially	successful,	 in	part	because	of	variable	low	expression	of	the	 inserted	gene,	and	the	 inability	to	target	the	gene	to	the	required	organ	or	site	 in	the	body.	The	lung	is	a	difficult	organ	to	treat	because	of	size	and	the	stickiness	of	mucous		as	a	result	 of	 the	 disease.	 Although	 theoretically	 simple	 to	 perform	 such	 treatments,	 gene	therapy	 has	 had	 a	 large	 number	 of	 failures.	 The	 occurrence	 of	 accidental	 deaths,	 due	 to	over-zealous	treatment	and/or	over-	zealous	researchers	halted	research	for	a	number	of	years,	and	led	to	skepticism	and	lack	of	funding	for	some	time.		.	
	The	 reason	 for	 isolating	 adenosine	 phosphoribosyl	 transferase	 (APRT)	 deficient	mutants	of	mouse	L-cells	 in	my	lab,	was	to	use	them	as	targets	for	gene	therapy.	We	also		cloned		the	aprt	gene.	I	decided	to	use	adenovirus-5	as	a	vector,	previously	utilized	in	other	studies.`	 To	 test	 feasibility,	we	 infected	 (or	 transfected	with	DNA)	 aprt	mutant	mouse	L-cells	with	 an	 adenovirus	 containing	 the	 Chinese	 hamster	 aprt	 gene	DNA,	 inserted	 into	 a	non-essential	 region	 of	 the	 virus	 (known	 as	 the	 E3	 region)	 not	 required	 for	 viral	replication.	This	virus	was	constructed	by	Vincent	Konan,	a	Ph.D.	 student	 from	 the	 Ivory	Coast	while	 the	vector	was	developed	by	Frank	Graham	of	McMaster’s	University.	 	Frank	also		developed	the	technique	of	calcium	transformation,	a	technique	in	which	DNA	bound	to	 calcium	was	 taken	up	by	 cells	 in	 culture	 and	expressed	 for	 a	 long	 time,	 forming	what	were	called	stable	transformants	(1).		He	also	developed	the	techniques	for	cloning	foreign	genes	into	adenovirus.	We	used	mouse	L-cells	since	the	virus	does	not	replicate	in	mouse	cells	and	 thus	does	not	destroy	 them,	although	 the	 transgene	 is	expressed,	 implying	 that	the	virus	persists	 in	 the	cell	over	a	 long	period.	These	experiments	were	very	successful,	and	 this	 work	 formed	 Vincent’s	 MA	 thesis.	 Thus	 we	 could	 use	 adenovirus	 to	 transform	APRT	negative	mutant	cells	to	APRT	positive	cells.	Evidence	indicated	that	the	APRT	gene	was	 into	 the	mouse	 genome	 (DNA)	 at	 random	 locations.	 This	was	 the	 result	 of	 a	 double	recombinant	event	since	in	those	clones	examined	viral	DNA	was	lost.		This	project	was	then	joined	by	Qing	Wang,	a	Ph.D.	student	from	China	(Nanking).	Qing	was	a	very	serious	young	woman.		Unusual	for	Chinese	students,	she	was	a	practicing	Catholic,	married	and	had	a	young	child.	I	never	met	her	husband,	who	worked	as	a	watch	repair	man.		They	were	apparently	childhood	sweet-	hearts.		The	marriage	did	not	last	long.	She	divorced	him	before	completing	her	Ph.D.	and	when	she	left	Bloomington	she	had	the	custody	of	her	son	who	moved	with	her	to	California.	Qing	used	a	variety	of	constructs	of	the	CHO	aprt	gene,	and	transfected	known	CHO	mutants	with	 the	 recombinant	 adenovirus.	 	 Such	mutants	 after	 transfection	 had	 normal	levels	 of	 APRT.	 	 In	 order	 to	 get	 high	 levels	 of	 recombinants	 the	 APRT	 promoter	 region	appeared	 to	be	required.	The	 transductants,	as	 in	 the	case	of	 the	L-cells	described	above	appeared	to	be	the	result	of	double	cross-overs,	since	 little	viral	material	remained.	 	This	was	 targeted	recombination	and	not	a	random	event.	This	was	an	 important	observation	and	we	should	have	spent	more	 time	 investigating	 the	mechanism	of	recombination.	The	
fact	 that	 the	 aprt	 promoter	 was	 required	 for	 this	 event	 was	 also	 interesting	 since	 it	appeared	to	be	stronger	than	the	viral	promoter.	(2)		On	 completion	 of	 her	 Ph.D.	 Qing	 took	 a	 position	with	 Cell	 Genesis,	 a	 new	biotech	company	 in	Foster	City,	South	San	Francisco.	 	 Its	original	aim	was	to	produce	vectors	 for	gene	 therapy,	 and	 it	 later	 turned	 attention	 to	 the	 development	 of	 cancer	 vaccines	(stimulation	of	the	immune	system)	using	viral	vectors.	Qing	is	listed	as	first	inventor	on	a	patent	developing	new	adenovirus	constructs.	I	visited	Cell	Genesys	in	the	very	early	days	of	the	company	and	gave	a	talk	on	APRT	as	model	for	gene	therapy.	As	in	the	case	of	many	biotech	companies,	none	of	the	products	passed	phase	1	or	phase	2	trials,	and	Cell	Genesys	eventually	merged	with	another	drug	company	after	a	financial	collapse.		Qing	herself	has	since	 worked	 for	 a	 number	 of	 other	 biotech	 companies,	 married	 a	 Jewish	 engineer	 and	resides	in	Palo	Alto.			We	then	decided	to	use	the	consensus	interferon	gene,	supplied	by	Dr.	Larry	Blatt	of	Amgen	 in	 gene	 therapy	 experiments.	 The	 idea	was	 to	 clone	 the	 gene	 into	 a	 virus	 vector,	deliver	 it	 directly	 into	 tumors,	 check	 for	 interferon	 activity,	 and	 examine	 whether	 it	inhibited	tumor	growth.		We	first	cloned	the	gene	into	a	small	virus,	considered	useful	as	a	vector,	adeno-associated	virus	(AAV).	This	is	a	defective	virus	and	requires	adenovirus	for	growth.	 	Thus	the	recombinant	virus	was	grown	in	the	presence	of	adenovirus-5,	and	the	AAV	recombinants	harvested	and	separated	from	adenovirus.	The	consensus	IFN	under	a	zinc	promoter,	was	expressed	in	all	the	cells	infected	with	AAV	in	the	presence	of	zinc.		The	cloning	efficiency	of	the	tumor	cell	lines	was	greatly	reduced	by	the	interferon	gene.		When	the	transformed	tumor	cells	were	injected	into	nude	mice,	tumor	growth	did	not	occur	in	contrast	 to	untransformed	 tumors.	 Likewise	when	established	 tumors	were	 treated	with	other	cells	producing	the	consensus	interferon,	tumor	growth	was	inhibited.		Whether	the	tumor	regression	was	due	to	the	consensus	interferon	or	to	activation	of	other	components	of	the	immune	system	is	unclear	(3,	4).	In	collaboration	with	Larry	Blatt	we	constructed	a	number	of	viral	vectors	containing	the	consensus	 IFN	 gene.	 These	 were	 placed	 under	 different	 promoter	 sequences,	 and	transfected	 into	 the	 leukemic	 cell	 line	 K562.	 Such	 constructs	 reversed	 the	 tumorgenic	phenotype	of	the	leukemic	cells.		
Much	of	this	work	was	done	by	a	post-doc,	Yipping	Geng.	Yipping	had	the	equivalent	of	a	Chinese	MD,	but	could	not	practice	medicine.		She	worked	very	hard,	and	on	leaving	my	lab	she	completed	her	M.D.	and	is	now	a	practicing	physician	in	the	New	York	City	area.	At	this	particular	point	in	time	I	had	a	very	large	group	of	students/post-docs	in	the	lab,	and	the	basic	 language	was	Chinese.	 	Apart	 from	Yipping	 there	was	 Jian	Zhang,	another	post-	doctoral	 fellow	 (or	 visiting	 scholar),	 very	 gifted	 with	 his	 hands,	 Chen	 Ju	 Hu,	 already	mentioned	elsewhere	and	Yanling	Huang	my	lab	technician.	The	next	stage	in	“	adventures”	in	gene	therapy		was	using	the	consensus	interferon	gene	in	the	adenovirus		vectors.	Here	our	aim	was	loftier,	to	inject	the	interferon	gene	into	nude	mice	with	human	breast	cancer	and	look	for	an	interferon	effect	on	the	tumor	growth	and	size.		We	injected	adenovirus	containing	the	consensus	interferon	gene	into	the	tumors	at	different	 times.	 The	 end	 point	 of	 these	 experiments	 was	 tumor	 regression.	 These	experiments	 were	 quite	 successful.	 Tumors	 regressed	 completely	 when	 the	 site	 was	injected	 with	 adenovirus/interferon.	 However	 the	 tumors	 also	 regressed	 when	 injected	just	with	 the	 adenovirus	 control,	 but	 not	when	 given	 saline.	 Interferon	 injection	 directly	also	had	 some	effect	 on	 the	 tumors	but	 less	 than	 the	 combination.	Thus	we	 appeared	 to	looking	at	a	viral-therapy	effect	as	well	as	an	effect	of	the	interferon.	(5)	This	 combination	was	 never	 tried	 on	 humans,	 perhaps	 because	 of	 a	 disaster	 that	occurred	 around	 this	 time	 at	 the	University	 of	 Pennsylvania	 in	 the	 treatment	 of	 a	 young	man	with	 adenovirus	 carrying	 a	 gene	 constructed	 to	 reverse	ornithine	 transcarbamylase	deficiency.	 Two	 investigators,	 Jim	 Wilson	 and	 Bill	 Kelly	 treated	 a	 young	 man,	 Jesse	Gelsinger,	age	18,	for	ornithine	transcarbamylase	deficiency	using	an	adenovirus	construct.	
Gelsinger suffered from OTD an X-linked genetic disease of the liver, the symptoms of 
which include an inability to metabolize ammonia - a byproduct of protein breakdown. 
The disease is usually fatal at birth, but Gelsinger had not inherited the disease; in his 
case it was apparently the result of a spontaneous genetic mutation after conception and 
as such was not as severe - some of his cells were normal which enabled him to survive 
on a restricted diet and special medications. It appears that an overdose of adenovirus was 
used resulting in an especially severe immune response.  Unfortunately the researchers 
made some very serious errors or judgment. They did not report adverse effects in other 
patients, nor the fact that monkeys had died after a similar dose of adenovirus. As a result 
of this accident NIH froze all gene therapy trials for a number of years.  A few years later 
another setback occurred using mouse leukemia virus as a vector in children suffering 
from combined immune-deficiency. Although for the first few years the treatment 
seemed to be effective, eventually four of the children developed leukemia, which 
resulted from insertion (recombination) of the virus into a location on the chromosome 
near an oncogene, thus activating this gene. This was a reflection of the randomness of 
the integration process.  Thus gene therapy has had a very checkered history and progress 
was delayed as a result. 
 Thus, although our results were positive, tumor did regress following treatment, it 
was the predominantly the result of viral oncolysis and not the expression of the 
interferon. By this time Amgen was no longer interested in the consensus interferon, they 
had sold it to a Japanese company, and it was near impossible to get funding for a 
continuation of gene therapy, so that this project basically died as a result of a low 
funding priority. As stated elsewhere, I should not have given up but resubmitted the 
grant proposal with novel ideas.  I learned only the other evening that adenovirus 
containing the interferon-alpha gene is being used or is in clinical trial for the treatment 
of bladder cancer.  
Certainly during the last few years Chinese scientists and a Chinese biotech 
company have been using viral vectors to treat various types of cancers, in particular 
glioblastoma in the brain. Amgen has developed a herpes virus that destroys melanoma 
cells, and an AAV has been modified for the treatment of a specific eye disease. There is 
no doubt that this is the way of the future for specific rare genetic diseases, and even for 
some type of cancers.  	This	was	a	period	when	my	lab	was	very	busy,	and	a	very	happy	place	to	work.	I	had	an	excellent	group	of	students,	and	they	interacted	with	each	other	very	well,	and	perhaps	at	times	were	a	little	too	zealous	in	trying	to	please	me.			
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